Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep? – Medscape
Medscape |
Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep?
Medscape One of the most important trials testing the role of immunotherapy combinations is MYSTIC, a phase 3 study of approximately 1100 advanced NSCLC patients randomly assigned to the PD-L1 inhibitor durvalumab with or without the CTLA-4 inhibitor … |
